Klin Farmakol Farm. 2025;39(4):236-240 | DOI: 10.36290/far.2025.051

Vasoactive drugs in the treatment of erectile dysfunction: current concepts

Markéta Rafajová
Urologická klinika 2. LF UK a FN Motol, Praha

Erectile dysfunction is a widespread health problem that significantly affects the quality of life of men. Pharmacotherapy is a key pillar of erectile dysfunction treatment, with vasoactive drugs, particularly phosphodiesterase type 5 inhibitors and prostaglandin E1, playing a crucial role in therapeutic approaches. This review article focuses on current concepts in the use of vasoactive drugs in the treatment of erectile dysfunction, including indications, mechanism of action, dosage, adverse effects and pharmacological interactions.

Keywords: erectile dysfunction, pharmacotherapy, phosphodiesterase type 5 inhibitors, prostaglandin E1.

Received: August 25, 2025; Revised: September 29, 2025; Accepted: October 8, 2025; Published: December 22, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rafajová M. Vasoactive drugs in the treatment of erectile dysfunction: current concepts. Klin Farmakol Farm. 2025;39(4):236-240. doi: 10.36290/far.2025.051.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Salonia A, Minhas S, Betocchi C, et al. Sexual and Reproductive Health. EAU Guidelines. Arnhem: EAU Guidelines Office; 2025. Dostupné také z: https://uroweb.org/guidelines/sexual-and-reproductive-health.
    2. Lewis RW, Fugl-Meyer KS, Bosch R, et al. Epidemiology/risk factors of sexual dysfunction. J Sex Med. 2004;1(1):35-39. Go to original source... Go to PubMed...
    3. Weiss P, Zvěřina J. Sexuální chování české populace. Urolog. pro Praxi. 2009;10(3):160-163.
    4. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163(2):460-463. Go to original source...
    5. Valicenti RK, Bissonette EA, Chen C, et al. Longitudinal comparison of sexual function after 3-dimensional conformal radiation therapy or prostate brachytherapy. J Urol. 2002;168(6):2499-2504. Go to original source...
    6. Vlachopoulos CV, Terentes‑Printzios DG, Ioakeimidis NK, et al. Prediction of cardiovascular events and all‑cause mortality with erectile dysfunction: a systematic review and meta‑analysis of cohort studies. Circ Cardiovasc Qual Outcomes. 2013;6(1):99-109. Go to original source... Go to PubMed...
    7. Hodges LD, Kirby M, Solanki J, et al. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. 2007;61(12):2019-2025. Go to original source... Go to PubMed...
    8. Gandaglia G, Briganti A, Jackson G, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol. 2014;65(5):968-978. Go to original source... Go to PubMed...
    9. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):596-646. Go to original source... Go to PubMed...
    10. Kloner RA, Burnett AL, Miner M, et al. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health. J Sex Med. 2024;30;21(2):90-116. Go to original source... Go to PubMed...
    11. Maiorino MI, Bellastella G, Esposito K. Lifestyle modifications and erectile dysfunction: what can be expected? Asian J Androl. 2015;17(1):5-10. Go to original source... Go to PubMed...
    12. Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13(4):465-488. Go to original source... Go to PubMed...
    13. Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs. 2005;65(12):1621-1650. Go to original source... Go to PubMed...
    14. Goldstein I, Lue TF, Padma‑Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998;338(20):1397-1404. Go to original source... Go to PubMed...
    15. Moncada I, Jara J, Subirá D, et al. Efficacy of sildenafil citrate at 12 hours after dosing: re‑exploring the therapeutic window. Eur Urol. 2004;46(3):357-361. Go to original source... Go to PubMed...
    16. SmPC jednotlivých léčivých přípravků, dostupné z Databáze léků. Státní ústav pro kontrolu léčiv [online], SÚKL: ©2035 [cit. 25.05.2025]. Dostupné na: https://www.sukl.cz/.
    17. Curran M, Keating G. Tadalafil. Drugs. 2003;63(20): 2203-2214. Go to original source... Go to PubMed...
    18. Capogrosso P, Ventimiglia E, Boeri L, et al. Time of onset of vardenafil orodispersible tablet in a real-life setting - loo­king beyond randomized clinical trials. Expert Rev Clin Pharmacol. 2017;10(3):339-344. Go to original source... Go to PubMed...
    19. Chung E, Broc GB. A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases. Expert Opin Pharmacother. 2011;12(8):1341-1348. Go to original source... Go to PubMed...
    20. Corona G, Rastrelli G, Burri A, et al. The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta‑analysis. Expert Opin Drug Saf. 2016;15(2):237-247. Go to original source... Go to PubMed...
    21. Coombs PG, Heck M, Guhring P, et al. A review of outcomes of an intracavernosal injection therapy programme. BJU Int. 2012;110(11):1787-1791. Go to original source... Go to PubMed...
    22. Eardley I, Donatucci C, Corbin J, et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010;7(1 Pt 2):524-540. Go to original source... Go to PubMed...
    23. Lakin MM, Montague DK, VanderBrug Medendorp S, et al. Intracavernous injection therapy: analysis of results and complications. J Urol. 1990;143(6):1138-1141. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.